<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="deo270086" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">DEN Open</journal-id><journal-id journal-id-type="iso-abbrev">DEN Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2692-4609</journal-id><journal-id journal-id-type="publisher-id">DEO2</journal-id><journal-title-group><journal-title>DEN Open</journal-title></journal-title-group><issn pub-type="epub">2692-4609</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40017510</article-id><article-id pub-id-type="pmc">PMC11865013</article-id>
<article-id pub-id-type="doi">10.1002/deo2.70086</article-id><article-id pub-id-type="publisher-id">DEO270086</article-id><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Endoscopic risk factors to inform early detection of gastric cancer after <italic toggle="yes">Helicobacter pylori</italic> eradication: Meta&#x02010;analysis and systematic review</article-title><alt-title alt-title-type="left-running-head">KODAMA et&#x000a0;al.</alt-title></title-group><contrib-group><contrib id="deo270086-cr-0001" contrib-type="author" corresp="yes"><name><surname>Kodama</surname><given-names>Masaaki</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0131-9470</contrib-id><xref rid="deo270086-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="deo270086-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>kodm@oita-u.ac.jp</email></address></contrib><contrib id="deo270086-cr-0002" contrib-type="author"><name><surname>Handa</surname><given-names>Osamu</given-names></name><xref rid="deo270086-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="deo270086-cr-0003" contrib-type="author"><name><surname>Sugimoto</surname><given-names>Mitsushige</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9194-7392</contrib-id><xref rid="deo270086-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="deo270086-cr-0004" contrib-type="author"><name><surname>Kotachi</surname><given-names>Takahiro</given-names></name><xref rid="deo270086-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="deo270086-cr-0005" contrib-type="author"><name><surname>Kobayashi</surname><given-names>Masaaki</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2766-642X</contrib-id><xref rid="deo270086-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="deo270086-cr-0006" contrib-type="author"><name><surname>Take</surname><given-names>Susumu</given-names></name><xref rid="deo270086-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="deo270086-cr-0007" contrib-type="author"><name><surname>Hoteya</surname><given-names>Shu</given-names></name><xref rid="deo270086-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="deo270086-cr-0008" contrib-type="author"><name><surname>Mabe</surname><given-names>Katsuhiro</given-names></name><xref rid="deo270086-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="deo270086-cr-0009" contrib-type="author"><name><surname>Murao</surname><given-names>Takahisa</given-names></name><xref rid="deo270086-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="deo270086-cr-0010" contrib-type="author"><name><surname>Namikawa</surname><given-names>Ken</given-names></name><xref rid="deo270086-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="deo270086-cr-0011" contrib-type="author"><name><surname>Kawai</surname><given-names>Takashi</given-names></name><xref rid="deo270086-aff-0012" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib id="deo270086-cr-0012" contrib-type="author"><name><surname>Murakami</surname><given-names>Kazunari</given-names></name><xref rid="deo270086-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo270086-cr-0013" contrib-type="author"><collab collab-type="authors">Research committee for the Establishment of Risk Evaluation of Gastric Cancer after H. pylori Eradication in Endoscopic Findings, The Japanese Society for Helicobacter Research, Japan</collab></contrib></contrib-group><aff id="deo270086-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Advanced Medical Sciences</named-content>
<named-content content-type="organisation-division">Faculty of Medicine</named-content>
<institution>Oita University</institution>
<city>Oita</city>
<country country="JP">Japan</country>
</aff><aff id="deo270086-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology</named-content>
<named-content content-type="organisation-division">Faculty of Medicine</named-content>
<institution>Oita University</institution>
<city>Oita</city>
<country country="JP">Japan</country>
</aff><aff id="deo270086-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology and Hepatology</named-content>
<institution>Kawasaki Medical School</institution>
<city>Okayama</city>
<country country="JP">Japan</country>
</aff><aff id="deo270086-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Division of Genome&#x02010;Wide Infectious Diseases</named-content>
<named-content content-type="organisation-division">Research Center for GLOBAL and LOCAL Infectious Diseases</named-content>
<institution>Oita University</institution>
<city>Oita</city>
<country country="JP">Japan</country>
</aff><aff id="deo270086-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology</named-content>
<institution>Hiroshima University Hospital</institution>
<city>Hiroshima</city>
<country country="JP">Japan</country>
</aff><aff id="deo270086-aff-0006">
<label>
<sup>6</sup>
</label>
<institution>Division of Gastroenterology, Niigata Cancer Center Hospital</institution>
<city>Niigata</city>
<country country="JP">Japan</country>
</aff><aff id="deo270086-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Gastrointestinal Endoscopy</named-content>
<institution>Nippon Kokan Fukuyama Hospital</institution>
<city>Okayama</city>
<country country="JP">Japan</country>
</aff><aff id="deo270086-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology</named-content>
<institution>Toranomon Hospital</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><aff id="deo270086-aff-0009">
<label>
<sup>9</sup>
</label>
<institution>Mabe Goryokaku Gastrointestinal Endoscopy Clinic</institution>
<city>Hokkaido</city>
<country country="JP">Japan</country>
</aff><aff id="deo270086-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Department of Health Care Medicine</named-content>
<institution>Kawasaki Medical School General Medical Center</institution>
<city>Okayama</city>
<country country="JP">Japan</country>
</aff><aff id="deo270086-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology</named-content>
<institution>Cancer Institute Hospital, Japanese Foundation for Cancer Research</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><aff id="deo270086-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterological Endoscopy</named-content>
<institution>Tokyo Medical University Hospital</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Masaaki Kodama, Department of Advanced Medical Sciences, Faculty of Medicine, Oita University, 1&#x02010;1, Idaigaoka, Hasama&#x02010;machi, Yufu, Oita, 879&#x02010;5593, Japan.<break/> Email: <email>kodm@oita-u.ac.jp</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>5</volume><issue seq="28">1</issue><issue-id pub-id-type="doi">10.1002/deo2.v5.1</issue-id><elocation-id>e70086</elocation-id><history>
<date date-type="rev-recd"><day>03</day><month>2</month><year>2025</year></date>
<date date-type="received"><day>13</day><month>11</month><year>2024</year></date>
<date date-type="accepted"><day>14</day><month>2</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">DEN Open</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DEO2-5-e70086.pdf"/><abstract><title>Abstract</title><sec id="deo270086-sec-0010"><title>Objectives</title><p>
<italic toggle="yes">Helicobacter pylori</italic> eradication reduces but cannot eliminate the risk of gastric cancer (GC). The prevalence of post&#x02010;eradication GC has been rising. Characterization of the endoscopic findings of post&#x02010;eradication GC may facilitate its early detection. We performed a meta&#x02010;analysis and systematic review to clarify endoscopic risk factors to accelerate the early diagnosis of post&#x02010;eradication GC.</p></sec><sec id="deo270086-sec-0020"><title>Methods</title><p>Medline and PubMed were searched for randomized controlled trials, cohort studies, and case&#x02010;control studies published in the English&#x02010;language medical literature between January 1997 and July 2023. The included articles assessed the correlation between post&#x02010;eradication GC and pre&#x02010; and post&#x02010;eradication endoscopic findings, and associated post&#x02010;eradication GC with gastric atrophy, intestinal metaplasia (IM), map&#x02010;like redness, and xanthoma.</p></sec><sec id="deo270086-sec-0030"><title>Results</title><p>A total of 963 articles were retrieved. In these articles, 66 papers were finally included, comprising randomized controlled trials, cohort studies, and case&#x02010;control studies. The included articles addressed gastric atrophy (16 studies), IM (eight studies), map&#x02010;like redness (six studies), and xanthoma (two studies). Risk ratio (RR) of incident post&#x02010;eradication GC was 3.40 (95%confidence interval [95%CI]: 1.98&#x02013;5.84; <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001) in cases of severe atrophy, 5.38 (95%CI: 3.62&#x02013;8.00) in cases of severe IM, 2.34 (95%CI: 1.16&#x02013;4.68) in cases with post&#x02010;eradication map&#x02010;like redness, and 2.75 (95% CI: 1.78&#x02013;4.26) in cases with xanthoma.</p></sec><sec id="deo270086-sec-0040"><title>Conclusions</title><p>Endoscopic atrophy, IM, and xanthoma observed at pre&#x02010; and post&#x02010;eradication time points and post&#x02010;eradication map&#x02010;like redness were suggested as endoscopic risk factors for post&#x02010;eradication GC. Further studies are needed to clarify the risk of post&#x02010;eradication GC based on these risk factors.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="deo270086-kwd-0001">atrophic gastritis</kwd><kwd id="deo270086-kwd-0002">eradication</kwd><kwd id="deo270086-kwd-0003">gastric cancer</kwd><kwd id="deo270086-kwd-0004"><italic toggle="yes">Helicobacter pylori</italic></kwd><kwd id="deo270086-kwd-0005">intestinal metaplasia</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>The Japanese Society for</funding-source></award-group><award-group id="funding-0002"><funding-source>Helicobacter</funding-source></award-group><award-group id="funding-0003"><funding-source>Research</funding-source></award-group></funding-group><counts><fig-count count="8"/><table-count count="5"/><page-count count="16"/><word-count count="7494"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:07.04.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="deo270086-sec-0050"><title>INTRODUCTION</title><p>Gastric cancer (GC) is the fifth most prevalent cancer worldwide and the fourth leading cause of cancer mortality.<xref rid="deo270086-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="deo270086-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> GC incidence is highest in Japan, where attributable mortality may reach 40,000 deaths annually. <italic toggle="yes">Helicobacter pylori</italic> infection is the major etiology of GC and is implicated in up to 90% of cases.<xref rid="deo270086-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="deo270086-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
<italic toggle="yes">H. pylori</italic> eradication reduces GC incidence, but only by 60%&#x02013;70%.<xref rid="deo270086-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="deo270086-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="deo270086-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="deo270086-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> In addition, GC can occur more than ten years after eradication,<xref rid="deo270086-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> thereby posing a lifelong risk. With increased numbers of patients undergoing <italic toggle="yes">H. pylori</italic> eradication, the prevalence of post&#x02010;eradication GC has been rising.<xref rid="deo270086-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p><p>Endoscopic and histologic features of post&#x02010;eradication GC differ from those of <italic toggle="yes">H. pylori</italic>&#x02010;positive cases.<xref rid="deo270086-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="deo270086-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Endoscopic diagnosis is difficult, for example, due to the gastritis&#x02010;like appearance of gastric epithelium with low&#x02010;grade atypia.<xref rid="deo270086-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="deo270086-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="deo270086-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Consequently, the identification of risk factors of post&#x02010;eradication GC is important to accelerate early&#x02010;stage diagnosis and treatment. Although multiple studies have reported the characteristics and risk factors of post&#x02010;eradication GC<xref rid="deo270086-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="deo270086-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="deo270086-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="deo270086-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="deo270086-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="deo270086-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="deo270086-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> and have demonstrated that <italic toggle="yes">H. pylori</italic> eradication suppresses GC,<xref rid="deo270086-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="deo270086-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="deo270086-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="deo270086-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="deo270086-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> none have comprehensively analyzed endoscopic findings as risk factors for post&#x02010;eradication GC. Consequently, the Research Committee for the Establishment of Risk Evaluation of GC after <italic toggle="yes">H. pylori</italic> Eradication in Endoscopic Findings, established by the Japanese Society for <italic toggle="yes">Helicobacter</italic> Research, performed a systematic review and meta&#x02010;analysis to clarify endoscopic risk factors to facilitate the early diagnosis of post&#x02010;eradication GC.</p></sec><sec id="deo270086-sec-0060"><title>MATERIALS AND METHODS</title><sec id="deo270086-sec-0070"><title>Search strategy and selection criteria</title><p>We searched the PubMed and Medline registries according to the Preferred Reporting Items for Systematic Reviews and Meta&#x02010;Analysis (PRISMA) guidelines (PRISMA 2020 Checklist in <xref rid="deo270086-supinfo-0001" ref-type="">Supporting Information</xref>). The search was conducted using the following terms: &#x02018;Stomach Neoplasms&#x02019; [MeSH Major Topic], &#x02018;pylori,&#x02019; and &#x02018;eradication,&#x02019; and &#x02018;(after or following or post or past).&#x02019; Inclusion criteria were (1) evaluation of the association between <italic toggle="yes">H. pylori</italic> eradication and post&#x02010;eradication GC; and (2) evaluation of the correlation of endoscopic findings to post&#x02010;eradication GC. Included study designs comprised randomized controlled trials (RCTs), prospective cohort studies, retrospective cohort studies, and case&#x02010;control studies published in the English&#x02010;language medical literature from January 1993 to July 2023.</p></sec><sec id="deo270086-sec-0080"><title>Study design and data collection</title><p>Eight investigators of the study committee (Masaaki Kodama, Osamu Handa, Mitsushige Sugimoto, Takahiro Kotachi, Masaaki Kobayashi, Susumu Take, Syu Hoteya, and Takahisa Murao) each independently screened titles and abstracts and then evaluated the full texts of the selected articles. Case reports and review articles, studies regarding gastric lesions other than post&#x02010;eradication GC (e.g., mucosa&#x02010;associated lymphoid tissue lymphoma, adenoma, and hyperplastic polyps; dysplasia; gastric ulcer; GC but not after eradication) were excluded. Basic research articles and clinical studies without assessments of risk factors or endoscopic findings were excluded. All articles that were considered necessary but not identified by this search strategy were hand&#x02010;searched for inclusion. Finally, committee members discussed and determined the validity of the collected literature.</p></sec><sec id="deo270086-sec-0090"><title>Outcomes</title><p>The primary outcome was the development of post&#x02010;eradication GC. The period from eradication to GC diagnosis was recognized as more than 1 year but followed the case definitions of the respective studies. Asymptomatic cases in healthy subjects or first GC development after <italic toggle="yes">H. pylori</italic> eradication indicated for the treatment of benign diseases such as peptic ulcer were defined as cases without GC at baseline. Metachronous GC after endoscopic resection of early GC was defined as cases with GC at baseline. Baseline factors, comorbidities, endoscopic findings, histologic findings, and medications that were not analyzed and correlated with post&#x02010;eradication GC were excluded.</p><p>The secondary outcome was the relationship of specific endoscopic findings to incident post&#x02010;eradication GC. Endoscopic findings associated with post&#x02010;eradication GC in the collected articles included atrophy, intestinal metaplasia (IM), map&#x02010;like redness, and xanthoma.</p><p>Atrophy comprises both histologic and endoscopic atrophy. Histologic atrophy was defined in enrolled studies by the updated Sydney system using a visual analog scale<xref rid="deo270086-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> and was classified as normal, mild, moderate, and marked. Endoscopic atrophy was defined by the Kimura&#x02010;Takemoto classification, that is, close&#x02010;type and open&#x02010;type atrophy were further classified as: none (C&#x02010;0), mild (C&#x02010;1, C&#x02010;2), moderate (C&#x02010;3, O&#x02010;1), and severe (O&#x02010;2, O&#x02010;3).<xref rid="deo270086-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> Included articles also addressed endoscopic findings of IM in the antrum and the corpus; the onset of map&#x02010;like redness after <italic toggle="yes">H. pylori</italic> eradication<xref rid="deo270086-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>; and the presence of xanthomas.</p><p>Atrophy due to <italic toggle="yes">H. pylori</italic> infection reduces the acidity of the gastric environment, which induces IM at atrophied sites. Therefore, atrophy and IM are strongly correlated. Narrow band imaging (Olympus) and Blue laser imaging (Fujifilm) disclose light blue crests and a white opaque substance as characteristic findings on the IM surface layer.<xref rid="deo270086-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="deo270086-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>
</p><p>Most endoscopic findings associated with <italic toggle="yes">H. pylori</italic> infection, such as petechial and diffuse erythema, accompany current infection but often decrease or resolve after eradication. Map&#x02010;like redness appears after eradication and persists thereafter.<xref rid="deo270086-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Map&#x02010;like redness consists of depressed and variously shaped erythema formed by the difference in change between IM and the surrounding mucosa after successful eradication. Not all IM lesions develop post&#x02010;eradication map&#x02010;like redness; incidence is 20%&#x02013;30% one year after eradication.<xref rid="deo270086-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="deo270086-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>
</p></sec><sec id="deo270086-sec-0100"><title>Statistical analysis</title><p>Heterogeneity was evaluated by <italic toggle="yes">I</italic>
<sup>2</sup> value and Cochran's Q. The <italic toggle="yes">I</italic>
<sup>2</sup> value was used to assess the heterogeneity of the studies as follows: 0%&#x02013;39%, low heterogeneity; 40%&#x02013;74%, moderate heterogeneity; and 75%&#x02013;100%, high heterogeneity. The risk ratio (RR) and 95% confidence interval (CI) of each study were reported as the measure of effect size. Mainly random&#x02010;effects model was used for the evaluation of each model, in addition, the fixed&#x02010;effects model was also calculated. Publication bias was assessed using funnel plots. All meta&#x02010;analyses were conducted using open&#x02010;source statistical software (Review Manager Version 5.3. Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration, 2014). All <italic toggle="yes">p&#x02010;</italic>values were two&#x02010;sided, and <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.05 was considered statistically significant.</p></sec></sec><sec id="deo270086-sec-0110"><title>RESULTS</title><sec id="deo270086-sec-0120"><title>Data extraction</title><p>A total of 963 articles were retrieved. Articles that did not report original research (review articles, case reports; n&#x000a0;=&#x000a0;71); that did not describe post&#x02010;eradication GC; that did not evaluate endoscopic findings; or that reported basic research (n&#x000a0;=&#x000a0;519) were excluded. A total of 66 papers were finally included, comprising RCTs, cohort studies, and case&#x02010;control studies. Four endoscopic findings comprising atrophy, IM, map&#x02010;like redness, and xanthoma were analyzed in these articles as factors associated with post&#x02010;eradication GC. Therefore, articles were selected and analyzed based on these four endoscopic findings (Figure&#x000a0;<xref rid="deo270086-fig-0001" ref-type="fig">1</xref>).</p><fig position="float" fig-type="FIGURE" id="deo270086-fig-0001"><label>FIGURE 1</label><caption><p>Flow diagram of search and study selection. Flow diagram of search and study selection according to Preferred Reporting Items for Systematic Reviews and Meta&#x02010;Analyses (PRISMA) guidelines (PRISMA 2020 Checklist in Supporting information). The included articles addressed gastric atrophy (16 studies), intestinal metaplasia (eight studies), map&#x02010;like redness (six studies), and xanthoma (two studies).</p></caption><graphic xlink:href="DEO2-5-e70086-g007" position="anchor" id="jats-graphic-1"/></fig></sec><sec id="deo270086-sec-0130"><title>Meta&#x02010;analysis</title><p>Of the 66 collected articles, 34 addressed atrophy, 28 evaluated IM, six described map&#x02010;like redness, and two that evaluated xanthomas were selected as references that analyzed relationships between endoscopic findings and post&#x02010;eradication GC. Of these, 15 articles on atrophy, eight on IM, six on map&#x02010;like redness, and two on xanthoma were finally selected for meta&#x02010;analysis. Overall, 19 articles were analyzed after duplicates were excluded.</p></sec><sec id="deo270086-sec-0140"><title>Atrophy</title><p>Five of the 16 articles subjected to meta&#x02010;analysis evaluated histologic atrophy and 11 analyzed endoscopic atrophy. Nine articles studied cases with pre&#x02010;eradication GC, and seven articles analyzed cases without GC at baseline. Definitions of severe, mild, or no atrophy differed between articles, with some articles classifying only by the presence of atrophy and others using the Kimura&#x02010;Takemoto classification, with O&#x02010;2 and O&#x02010;3 signifying severe and C0&#x02010;C2 representing absent or mild atrophy (Table&#x000a0;<xref rid="deo270086-tbl-0001" ref-type="table">1</xref>). A total of 378 of 4086 patients with severe atrophy developed post&#x02010;eradication GC, compared to 158 of 5135 cases with no or mild atrophy. The corresponding forest plot is shown in Figure&#x000a0;<xref rid="deo270086-fig-0002" ref-type="fig">2</xref>. The overall RR for the onset of post&#x02010;eradication GC among patients with severe atrophy was 3.40 (95%CI: 1.98&#x02013;5.84; <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001) compared to no or mild atrophy. The evaluation of heterogeneity disclosed an <italic toggle="yes">I</italic>
<sup>2</sup> of 81% (Figure&#x000a0;<xref rid="deo270086-fig-0002" ref-type="fig">2</xref>), (Fixed&#x02010;effects model is shown in Figure <xref rid="deo270086-supinfo-0001" ref-type="">S1</xref>).</p><table-wrap position="float" id="deo270086-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Baseline characteristics of studies that indicated a correlation between atrophy and post&#x02010;eradication gastric cancer.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Author</th><th align="left" rowspan="1" colspan="1">Year</th><th align="left" rowspan="1" colspan="1">Country</th><th align="left" rowspan="1" colspan="1">Study Design</th><th align="left" rowspan="1" colspan="1">Baseline GC</th><th align="left" rowspan="1" colspan="1">Atrophy, histological, or endoscopic</th><th align="left" rowspan="1" colspan="1">Sample size (Eradication cases)</th><th align="left" rowspan="1" colspan="1">GC cases after eradication</th><th align="left" rowspan="1" colspan="1">Risk ratio</th><th align="left" rowspan="1" colspan="1">95&#x0ff05; CI</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p&#x02010;</italic>value</th><th align="left" rowspan="1" colspan="1">Comment</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Wong BCY<xref rid="deo270086-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">RCT</td><td align="left" rowspan="1" colspan="1">Without GC</td><td align="left" rowspan="1" colspan="1">Histological</td><td align="left" rowspan="1" colspan="1">817</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">HR: 2.97</td><td align="left" rowspan="1" colspan="1">0.94&#x02013;9.42</td><td align="left" rowspan="1" colspan="1">0.06</td><td align="left" rowspan="1" colspan="1">Precancerous lesion (histological atrophy, IM, dysplasia) HR: 2.97 (0.94&#x02013;9.42) &#x000a0;.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Kamada T<xref rid="deo270086-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">Cohort</td><td align="left" rowspan="1" colspan="1">Without GC</td><td align="left" rowspan="1" colspan="1">Histological</td><td align="left" rowspan="1" colspan="1">1787</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GC/Atrophic gastritis: 2/453(0.4&#x0ff05;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hanaoka N<xref rid="deo270086-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2010</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">Cohort</td><td align="left" rowspan="1" colspan="1">With GC</td><td align="left" rowspan="1" colspan="1">Endoscopic</td><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">HR: 4.88</td><td align="left" rowspan="1" colspan="1">1.32&#x02013;18.2</td><td align="left" rowspan="1" colspan="1">0.018</td><td align="left" rowspan="1" colspan="1">Open&#x02010;type atrophy diagnosed by AFI was significantly associated with metachronous GC (HR: 4.88, 95%CI: 1.32&#x02013;18.2, <italic toggle="yes">p</italic>&#x000a0;= 0.018)</td></tr><tr><td align="left" rowspan="1" colspan="1">Take S<xref rid="deo270086-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2011</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">Cohort</td><td align="left" rowspan="1" colspan="1">Without GC</td><td align="left" rowspan="1" colspan="1">Endoscopic</td><td align="left" rowspan="1" colspan="1">1674</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">HR: 14.4</td><td align="left" rowspan="1" colspan="1">1.9&#x02013;110.2</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">GC group: Severe atrophy at Baseline (HR: 14.4;95&#x0ff05;CI: 1.9&#x02013;110.2, <italic toggle="yes">p</italic>=0&#x000a0;.01&#x000a0;vs. mild atrophy)</td></tr><tr><td align="left" rowspan="1" colspan="1">Maehata Y<xref rid="deo270086-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2012</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">R Cohort</td><td align="left" rowspan="1" colspan="1">With GC</td><td align="left" rowspan="1" colspan="1">Endoscopic</td><td align="left" rowspan="1" colspan="1">177</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">OR: 2.71</td><td align="left" rowspan="1" colspan="1">1.07&#x02013;7.97</td><td align="left" rowspan="1" colspan="1">0.036</td><td align="left" rowspan="1" colspan="1">Severe atrophy; OR: 2.71 (1.07&#x02013;7.97) <italic toggle="yes">p</italic>&#x000a0;= 0.036</td></tr><tr><td align="left" rowspan="1" colspan="1">Kwon YH<xref rid="deo270086-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2014</td><td align="left" rowspan="1" colspan="1">Korea</td><td align="left" rowspan="1" colspan="1">R Cohort</td><td align="left" rowspan="1" colspan="1">With GC</td><td align="left" rowspan="1" colspan="1">Endoscopic</td><td align="left" rowspan="1" colspan="1">214</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Risk of GC is HP infection OR 2.322, Age 60 years old &#x02267;(OR: 2.803), Endoscopic atrophy showed no significance</td></tr><tr><td align="left" rowspan="1" colspan="1">Shichijo S<xref rid="deo270086-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2016</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">Cohort</td><td align="left" rowspan="1" colspan="1">Without GC</td><td align="left" rowspan="1" colspan="1">Histological</td><td align="left" rowspan="1" colspan="1">573</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">HR: 9.3</td><td align="left" rowspan="1" colspan="1">1.7&#x02013;174</td><td align="left" rowspan="1" colspan="1">0.007</td><td align="left" rowspan="1" colspan="1">Severe atrophy (O2&#x02010;O3): 12 of 97 cases HR: 9.3 95%CI: 1.7&#x02013;174, <italic toggle="yes">p</italic>&#x000a0;= 0.007&#x000a0;versus. non&#x02010;mild Atrophy (C0&#x02010;C2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Toyoshima O<xref rid="deo270086-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">R Cohort</td><td align="left" rowspan="1" colspan="1">Without GC</td><td align="left" rowspan="1" colspan="1">Endoscopic</td><td align="left" rowspan="1" colspan="1">1232</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">HR: 1.7</td><td align="left" rowspan="1" colspan="1">1.12&#x02013;2.78</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">Atrophy;(HR: 1.7, 1.12&#x02013;2.78 0.01)</td></tr><tr><td align="left" rowspan="1" colspan="1">Choi JM <xref rid="deo270086-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2018</td><td align="left" rowspan="1" colspan="1">Korea</td><td align="left" rowspan="1" colspan="1">RCT</td><td align="left" rowspan="1" colspan="1">With GC</td><td align="left" rowspan="1" colspan="1">Histological</td><td align="left" rowspan="1" colspan="1">442</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GC incidence of no&#x02010;Corpus Atrophy 3/134, corpus atrophy 15/289</td></tr><tr><td align="left" rowspan="1" colspan="1">Shibukawa N<xref rid="deo270086-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2019</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">Case Control</td><td align="left" rowspan="1" colspan="1">With GC</td><td align="left" rowspan="1" colspan="1">Endoscopic</td><td align="left" rowspan="1" colspan="1">184</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">OR: 3.06</td><td align="left" rowspan="1" colspan="1">1.10&#x02013;8.49</td><td align="left" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">Atrophy (open type): OR 3.06 (1.10&#x02013;8.49) 0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Take S<xref rid="deo270086-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">R Cohort</td><td align="left" rowspan="1" colspan="1">Without GC</td><td align="left" rowspan="1" colspan="1">Endoscopic</td><td align="left" rowspan="1" colspan="1">2737</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GC incidence of severe atrophy 0.67%/year, versus moderate 0.29%/year, mild atrophy 0.15%/year</td></tr><tr><td align="left" rowspan="1" colspan="1">Kato M<xref rid="deo270086-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">Case Control</td><td align="left" rowspan="1" colspan="1">With GC</td><td align="left" rowspan="1" colspan="1">Endoscopic</td><td align="left" rowspan="1" colspan="1">294</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">HR: 1.20 times higher in the non&#x02010;eradicated group than in the eradicated group in the advanced atrophy group (<italic toggle="yes">p</italic>&#x000a0;= 0.52)</td></tr><tr><td align="left" rowspan="1" colspan="1">Yan X<xref rid="deo270086-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">R Cohort</td><td align="left" rowspan="1" colspan="1">With GC</td><td align="left" rowspan="1" colspan="1">Endoscopic</td><td align="left" rowspan="1" colspan="1">1961</td><td align="left" rowspan="1" colspan="1">132</td><td align="left" rowspan="1" colspan="1">OR: 8.08</td><td align="left" rowspan="1" colspan="1">3.43&#x02013;20.0</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="left" rowspan="1" colspan="1">Severe atrophy: (OR&#x000a0;= 8.08; 95% CI, 3.43&#x02010;20.0; <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.01)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hara D<xref rid="deo270086-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">Case Control</td><td align="left" rowspan="1" colspan="1">Without GC</td><td align="left" rowspan="1" colspan="1">Endoscopic</td><td align="left" rowspan="1" colspan="1">247</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">atrophy close type GC 1/11, open type GC10/11</td></tr><tr><td align="left" rowspan="1" colspan="1">Yan L<xref rid="deo270086-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">RCT</td><td align="left" rowspan="1" colspan="1">Without GC</td><td align="left" rowspan="1" colspan="1">Histological</td><td align="left" rowspan="1" colspan="1">817</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">HR: 0.37</td><td align="left" rowspan="1" colspan="1">0.15&#x02013;0.95</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Without precancerous lesion (histological atrophy, IM, dysplasia), HR: 0.37; 95% CI, 0.15&#x02013;0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">Wei Y<xref rid="deo270086-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">Case Control</td><td align="left" rowspan="1" colspan="1">With GC</td><td align="left" rowspan="1" colspan="1">Endoscopic</td><td align="left" rowspan="1" colspan="1">133</td><td align="left" rowspan="1" colspan="1">133</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Moderate/severe gastric atrophy, IM of the gastric body, severe diffuse erythema, and map&#x02010;like erythema are risk factors for EGC after eradication</td></tr></tbody></table><table-wrap-foot><fn id="deo270086-tbl1-note-0001"><p>Abbreviations: 95%CI: 95% Confidence Interval, GC: gastric cancer, HP: <italic toggle="yes">Helicobacter pylori</italic>, HR: hazard ratio, NA: not applicable, OR: odds ratio, RCT: randomized controlled trial, R cohort: retrospective cohort.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><fig position="float" fig-type="FIGURE" id="deo270086-fig-0002"><label>FIGURE 2</label><caption><p>Forest plot analyzing the occurrence of post&#x02010;eradication gastric cancer according to severity of gastric atrophy.</p></caption><graphic xlink:href="DEO2-5-e70086-g001" position="anchor" id="jats-graphic-3"/></fig></sec><sec id="deo270086-sec-0150"><title>Atrophy, sub&#x02010;analysis with and without GC at baseline</title><p>Due to the high heterogeneity in atrophy (81%), we performed sub&#x02010;analysis by a group of seven articles without GC and nine articles with GC (after endoscopic resection of GC) in the baseline as sensitivity analysis (Figure&#x000a0;<xref rid="deo270086-fig-0003" ref-type="fig">3</xref>), (Fixed&#x02010;effects model is shown in Figure <xref rid="deo270086-supinfo-0001" ref-type="">S2</xref>).</p><fig position="float" fig-type="FIGURE" id="deo270086-fig-0003"><label>FIGURE 3</label><caption><p>Forest plot analyzing the occurrence of post&#x02010;eradication gastric cancer according to the severity of gastric atrophy, Sub&#x02010;analysis with and without GC at baseline. (a) Forest plot of Atrophy without GC. (b) Forest plot of Atrophy with GC. GC: gastric cancer.</p></caption><graphic xlink:href="DEO2-5-e70086-g008" position="anchor" id="jats-graphic-5"/></fig><p>In the without GC group, RR of severe atrophy showed 5.07 (95%CI: 1.83&#x02013;14.01; <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.005) compared to no or mild atrophy. Heterogeneity was 68% (Figure&#x000a0;<xref rid="deo270086-fig-0003" ref-type="fig">3a</xref>). With the GC group, severe atrophy showed RR 2.81 (95%CI: 1.44&#x02013;5.50; <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) compared to no or mild atrophy. Heterogeneity was 86% (Figure&#x000a0;<xref rid="deo270086-fig-0003" ref-type="fig">3b</xref>).</p></sec><sec id="deo270086-sec-0160"><title>Intestinal metaplasia</title><p>Of the eight articles addressing IM that were subjected to meta&#x02010;analysis, three described endoscopic evaluation, and five reported histologic assessment (Table&#x000a0;<xref rid="deo270086-tbl-0002" ref-type="table">2</xref>). Criteria for determining the degree of IM were the presence or absence of IM, or the presence of IM limited to the antrum or extending to the corpus. In most articles, IM of the corpus was classified as severe IM. Post&#x02010;eradication GC was diagnosed in 307 of 1567 patients with severe IM and in 26 of 1857 patients without or with mild IM. RR of post&#x02010;eradication GC among patients with advanced IM was 5.38 (95%CI: 3.62&#x02013;8.00) compared to no or limited to the antrum (Figure&#x000a0;<xref rid="deo270086-fig-0004" ref-type="fig">4</xref>), (Fixe&#x02010;effects model is shown in Figure <xref rid="deo270086-supinfo-0001" ref-type="">S3</xref>). Heterogeneity was low, with an <italic toggle="yes">I</italic>
<sup>2</sup> value of 0% (Table&#x000a0;<xref rid="deo270086-tbl-0003" ref-type="table">3</xref>).</p><table-wrap position="float" id="deo270086-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Baseline characteristics of studies that correlated intestinal metaplasia with post&#x02010;eradication gastric cancer.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Author</th><th align="left" rowspan="1" colspan="1">Year</th><th align="left" rowspan="1" colspan="1">Country</th><th align="left" rowspan="1" colspan="1">Study design</th><th align="left" rowspan="1" colspan="1">Baseline GC</th><th align="left" rowspan="1" colspan="1">IM, histologic, or endoscopic</th><th align="left" rowspan="1" colspan="1">Eradication cases</th><th align="left" rowspan="1" colspan="1">GC cases after eradication</th><th align="left" rowspan="1" colspan="1">Risk ratio</th><th align="left" rowspan="1" colspan="1">95&#x0ff05; CI</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p&#x02010;</italic>Value</th><th align="left" rowspan="1" colspan="1">Comment</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Wong BCY<xref rid="deo270086-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">RCT</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">Histologic</td><td align="left" rowspan="1" colspan="1">817</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">HR 2.97</td><td align="left" rowspan="1" colspan="1">0.94&#x02010;9.42</td><td align="left" rowspan="1" colspan="1">0.06</td><td align="left" rowspan="1" colspan="1">Precancerous lesion (histological atrophy, IM, dysplasia), HR: 2.97 (0.94&#x02013;9.42), <italic toggle="yes">p</italic>&#x000a0;= 0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Moribata K<xref rid="deo270086-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2016</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">R. Cohort</td><td align="left" rowspan="1" colspan="1">+</td><td align="left" rowspan="1" colspan="1">Histologic</td><td align="left" rowspan="1" colspan="1">122</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Kaplan&#x02013;Meier curves indicated that patients without IM before ESD never developed metachronous cancer.</td></tr><tr><td align="left" rowspan="1" colspan="1">Shichijo S<xref rid="deo270086-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2016</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">Cohort</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">Histologic</td><td align="left" rowspan="1" colspan="1">573</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">HR 3.7</td><td align="left" rowspan="1" colspan="1">1.1&#x02010;12</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IM in the corpus: HR 3.7(95&#x0ff05;CI, 1.1&#x02013;12)versus non&#x02010;IM</td></tr><tr><td align="left" rowspan="1" colspan="1">Choi JM<xref rid="deo270086-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2018</td><td align="left" rowspan="1" colspan="1">Korea</td><td align="left" rowspan="1" colspan="1">RCT</td><td align="left" rowspan="1" colspan="1">+</td><td align="left" rowspan="1" colspan="1">Histologic</td><td align="left" rowspan="1" colspan="1">442</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Corpus IM 18/331, No corpus IM 0/106</td></tr><tr><td align="left" rowspan="1" colspan="1">Shibukawa N<xref rid="deo270086-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2019</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">Case control</td><td align="left" rowspan="1" colspan="1">+</td><td align="left" rowspan="1" colspan="1">Endoscopic</td><td align="left" rowspan="1" colspan="1">184</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">OR: 4.39</td><td align="left" rowspan="1" colspan="1">1.58&#x02010;12.2</td><td align="left" rowspan="1" colspan="1">0.005</td><td align="left" rowspan="1" colspan="1">IM: OR 4.39 (1.58&#x02013;12.2), <italic toggle="yes">p</italic>&#x000a0;= 0.005</td></tr><tr><td align="left" rowspan="1" colspan="1">Yan X<xref rid="deo270086-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">R. Cohort</td><td align="left" rowspan="1" colspan="1">+</td><td align="left" rowspan="1" colspan="1">Endoscopic</td><td align="left" rowspan="1" colspan="1">1961</td><td align="left" rowspan="1" colspan="1">132</td><td align="left" rowspan="1" colspan="1">OR: 2.16</td><td align="left" rowspan="1" colspan="1">0.51&#x02010;11.8</td><td align="left" rowspan="1" colspan="1">0.32</td><td align="left" rowspan="1" colspan="1">IM: (OR&#x000a0;= 2.16; 95% CI, 0.51&#x02013;11.8; <italic toggle="yes">p</italic>&#x000a0;= 0.32)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hara D<xref rid="deo270086-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">Case control</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">Endoscopic</td><td align="left" rowspan="1" colspan="1">247</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">OLGIM I/II: GC 1/11, OLGIM III/IV: GC10/11</td></tr><tr><td align="left" rowspan="1" colspan="1">Yan L<xref rid="deo270086-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">RCT</td><td align="left" rowspan="1" colspan="1">&#x02212;</td><td align="left" rowspan="1" colspan="1">Histologic</td><td align="left" rowspan="1" colspan="1">817</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">HR: 0.37</td><td align="left" rowspan="1" colspan="1">0.15&#x02013;0.95</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Without precancerous lesion (histological atrophy, IM, dysplasia) (HR: 0.37; 95% CI, 0.15&#x02013;0.95)</td></tr></tbody></table><table-wrap-foot><fn id="deo270086-tbl2-note-0001"><p>Abbreviations: 95%CI: 95% confidence interval, HR: hazard ratio, IM: intestinal metaplasia, NA: not applicable, OLGIM: operative&#x000a0;link on gastric intestinal metaplasia assessment, OR: odds ratio, RCT: randomized controlled trial, R cohort: retrospective cohort.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><fig position="float" fig-type="FIGURE" id="deo270086-fig-0004"><label>FIGURE 4</label><caption><p>Forest plot analyzing the occurrence of post&#x02010;eradication gastric cancer according to severity of intestinal metaplasia. IM: intestinal metaplasia.</p></caption><graphic xlink:href="DEO2-5-e70086-g005" position="anchor" id="jats-graphic-7"/></fig><table-wrap position="float" id="deo270086-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Baseline characteristics of studies that correlated map&#x02010;like redness and post&#x02010;eradication gastric cancer.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Author</th><th align="left" rowspan="1" colspan="1">Year</th><th align="left" rowspan="1" colspan="1">Country</th><th align="left" rowspan="1" colspan="1">Study design</th><th align="left" rowspan="1" colspan="1">Baseline GC</th><th align="left" rowspan="1" colspan="1">Number of cases</th><th align="left" rowspan="1" colspan="1">Emergence of map&#x02010;like redness (%)</th><th align="left" rowspan="1" colspan="1">OR</th><th align="left" rowspan="1" colspan="1">95% CI</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p&#x02010;</italic>value</th><th align="left" rowspan="1" colspan="1">Comments</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Moribata K<xref rid="deo270086-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">R. Cohort</td><td align="left" rowspan="1" colspan="1">+</td><td align="left" rowspan="1" colspan="1">122</td><td align="left" rowspan="1" colspan="1">32 (39/122)</td><td align="left" rowspan="1" colspan="1">3.61</td><td align="left" rowspan="1" colspan="1">1.41&#x02013;9.21</td><td align="left" rowspan="1" colspan="1">0.007</td><td align="left" rowspan="1" colspan="1">Map&#x02010;like redness in 64% (14/22) of patients who developed metachronous GC after eradication and in 25% (25/100) of those who did not develop metachronous GC.</td></tr><tr><td align="left" rowspan="1" colspan="1">Majima A<xref rid="deo270086-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2019</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">Case control</td><td align="left" rowspan="1" colspan="1">+</td><td align="left" rowspan="1" colspan="1">109</td><td align="left" rowspan="1" colspan="1">WLI: 61.5 (67/109) LCI: 78 (85/109)</td><td align="left" rowspan="1" colspan="1">2.05 (WLI) 3.62 (LCI)</td><td align="left" rowspan="1" colspan="1">
<p>1.09&#x02013;3.87</p>
<p>1.88&#x02013;6.97</p>
</td><td align="left" rowspan="1" colspan="1">
<p>0.03</p>
<p>0.0001</p>
</td><td align="left" rowspan="1" colspan="1">With LCI observation, map&#x02010;like redness was significantly higher in the GC after&#x02010;eradication group (45.9%) than in the non&#x02010;GC group (78%).</td></tr><tr><td align="left" rowspan="1" colspan="1">Ohno A<xref rid="deo270086-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">Case control</td><td align="left" rowspan="1" colspan="1">Both + and &#x02212;</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">60.5 (26/43)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Map&#x02010;like redness was significantly higher in post eradication GC group (60.5%) than in the non&#x02010;GC group (31.1%).</td></tr><tr><td align="left" rowspan="1" colspan="1">Yan X<xref rid="deo270086-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">R. Cohort</td><td align="left" rowspan="1" colspan="1">+</td><td align="left" rowspan="1" colspan="1">162</td><td align="left" rowspan="1" colspan="1">89.5 (145/162)</td><td align="left" rowspan="1" colspan="1">1.75</td><td align="left" rowspan="1" colspan="1">1.11&#x02013;5.25</td><td align="left" rowspan="1" colspan="1">0.04</td><td align="left" rowspan="1" colspan="1">Map&#x02010;like redness was significantly higher in post eradication GC group (89.5%) than in the non&#x02010;GC group (65.4%).</td></tr><tr><td align="left" rowspan="1" colspan="1">Liu X<xref rid="deo270086-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">Case control</td><td align="left" rowspan="1" colspan="1">+</td><td align="left" rowspan="1" colspan="1">81</td><td align="left" rowspan="1" colspan="1">85.2 (69/81)</td><td align="left" rowspan="1" colspan="1">32.18</td><td align="left" rowspan="1" colspan="1">9.26&#x02013;111.77</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">Map&#x02010;like redness was significantly higher in post eradication GC group (85.2%, 69/81) than in the non&#x02010;GC group (13.3%, 14/105).</td></tr><tr><td align="left" rowspan="1" colspan="1">Wei Y<xref rid="deo270086-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2023</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">R. Cohort</td><td align="left" rowspan="1" colspan="1">+</td><td align="left" rowspan="1" colspan="1">133</td><td align="left" rowspan="1" colspan="1">41 (55/133)</td><td align="left" rowspan="1" colspan="1">1.21</td><td align="left" rowspan="1" colspan="1">0.55&#x02013;2.64</td><td align="left" rowspan="1" colspan="1">0.632</td><td align="left" rowspan="1" colspan="1">Map&#x02010;like redness was significantly higher in post eradication GC group (41%) than in the non&#x02010;GC group (24%).</td></tr></tbody></table><table-wrap-foot><fn id="deo270086-tbl3-note-0001"><p>Abbreviations: 95%CI: 95% confidence interval, GC: gastric cancer, HR: hazard ratio, LCI: linked color imaging, NA: not applicable, OR: odds ratio, RCT: randomized controlled trial, R cohort: retrospective cohort, WLI: white light imaging.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo270086-sec-0170"><title>Map&#x02010;like redness</title><p>The six articles that associated post&#x02010;eradication GC with map&#x02010;like redness were subjected to meta&#x02010;analysis (Table&#x000a0;<xref rid="deo270086-tbl-0005" ref-type="table">5</xref>) A fixed&#x02010;effects model is shown in Figure <xref rid="deo270086-supinfo-0001" ref-type="">S4</xref>). Because map&#x02010;like redness is a gross endoscopic finding, no histologic analyses were performed. A total of 402 of 665 patients with post&#x02010;eradication map&#x02010;like redness developed post&#x02010;eradication GC, compared with 159 of 549 patients without map&#x02010;like redness who developed post&#x02010;eradication GC. RR was 2.34 (95%CI: 1.16&#x02013;4.68) compared to no detection of map&#x02010;like redness. Heterogeneity was high, with an <italic toggle="yes">I</italic>
<sup>2</sup> value of 96% (Figure&#x000a0;<xref rid="deo270086-fig-0005" ref-type="fig">5a</xref>).</p><fig position="float" fig-type="FIGURE" id="deo270086-fig-0005"><label>FIGURE 5</label><caption><p>Forest plot analyzing the occurrence of post&#x02010;eradication gastric cancer according to post&#x02010;eradication onset of map&#x02010;like redness. (a) Forest plot analyzed using all articles. (b) Forest plot analyzed using selected two prospective cohort studies.</p></caption><graphic xlink:href="DEO2-5-e70086-g006" position="anchor" id="jats-graphic-9"/></fig><p>Map&#x02010;like redness had high heterogeneity (96%), therefore, subanalysis with only two articles of prospective cohort studies was performed. In this analysis, the RR was 2.54 (95%CI: 1.76&#x02013;3.66; <italic toggle="yes">p&#x000a0;</italic>=&#x000a0;0.83) compared to non&#x02010;Map&#x02010;like redness (Figure&#x000a0;<xref rid="deo270086-fig-0005" ref-type="fig">5b</xref>).</p></sec><sec id="deo270086-sec-0180"><title>Xanthoma</title><p>Both articles that associated post&#x02010;eradication GC and xanthoma confirmed the presence of xanthoma prior to <italic toggle="yes">H. pylori</italic> eradication and evaluated post&#x02010;eradication GC after endoscopic resection of early&#x02010;stage GC (Table&#x000a0;<xref rid="deo270086-tbl-0004" ref-type="table">4</xref>). Post&#x02010;eradication GC developed in 139 of 185 patients with xanthoma, compared with 93 of 323 patients without xanthoma. RR of developing post&#x02010;eradication GC among patients with xanthoma was 2.75 (95% CI: 1.78&#x02013;4.26) compared to no presence of xanthoma (Figure&#x000a0;<xref rid="deo270086-fig-0006" ref-type="fig">6</xref>); a fixed&#x02010;effects model is shown in Figure <xref rid="deo270086-supinfo-0001" ref-type="">S5</xref>. Heterogeneity was high, with an I<sup>2</sup> value of 75%. Publication bias, which was assessed by funnel plots, are shown in Figure <xref rid="deo270086-fig-0007" ref-type="fig">7</xref> (atrophy) and Figure <xref rid="deo270086-fig-0008" ref-type="fig">8</xref> (intestinal metaplasia, map&#x02010;like redness, and xanthoma). Funnel plots using a fixed&#x02010;effects model are shown in Figures <xref rid="deo270086-supinfo-0001" ref-type="">S6</xref> and <xref rid="deo270086-supinfo-0001" ref-type="">S7</xref>.</p><table-wrap position="float" id="deo270086-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Baseline characteristics of studies that correlated xanthoma and post&#x02010;eradication gastric cancer.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Author</th><th align="left" rowspan="1" colspan="1">Year</th><th align="left" rowspan="1" colspan="1">Country</th><th align="left" rowspan="1" colspan="1">Study design</th><th align="left" rowspan="1" colspan="1">Baseline GC</th><th align="left" rowspan="1" colspan="1">Xanthoma, histological, or endoscopic</th><th align="left" rowspan="1" colspan="1">Eradication cases</th><th align="left" rowspan="1" colspan="1">GC cases after eradication</th><th align="left" rowspan="1" colspan="1">Risk ratio</th><th align="left" rowspan="1" colspan="1">95&#x0ff05;CI</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th><th align="left" rowspan="1" colspan="1">Comment</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Shibukawa N<xref rid="deo270086-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2019</td><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">Case control</td><td align="left" rowspan="1" colspan="1">+</td><td align="left" rowspan="1" colspan="1">Endoscopic</td><td align="left" rowspan="1" colspan="1">184</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">OR: 5.64</td><td align="left" rowspan="1" colspan="1">2.47&#x02013;12.9</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">Xanthoma: OR 5.64 (2.47&#x02013;12.9), <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Yan X<xref rid="deo270086-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">R. Cohort</td><td align="left" rowspan="1" colspan="1">+</td><td align="left" rowspan="1" colspan="1">Endoscopic</td><td align="left" rowspan="1" colspan="1">1961</td><td align="left" rowspan="1" colspan="1">132</td><td align="left" rowspan="1" colspan="1">OR: 2.84</td><td align="left" rowspan="1" colspan="1">1.20&#x02013;7.03</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">Xanthoma: (OR 2.84; 95% CI, 1.20&#x02013;7.03; <italic toggle="yes">p</italic>&#x000a0;= 0.02)</td></tr></tbody></table><table-wrap-foot><fn id="deo270086-tbl4-note-0001"><p>Abbreviations: 95%CI: 95% confidence interval, OR: odds ratio, R cohort: retrospective cohort.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><fig position="float" fig-type="FIGURE" id="deo270086-fig-0006"><label>FIGURE 6</label><caption><p>Forest plot analyzing the incidence of post&#x02010;eradication gastric cancer according to the appearance of xanthoma.</p></caption><graphic xlink:href="DEO2-5-e70086-g004" position="anchor" id="jats-graphic-11"/></fig><fig position="float" fig-type="FIGURE" id="deo270086-fig-0007"><label>FIGURE 7</label><caption><p>Funnel plots of atrophy analyzed. (a) Atrophy of all 16 articles, (b) atrophy of seven articles without gastric cancer (GC), and (c) atrophy of nine articles with GC.</p></caption><graphic xlink:href="DEO2-5-e70086-g002" position="anchor" id="jats-graphic-13"/></fig><fig position="float" fig-type="FIGURE" id="deo270086-fig-0008"><label>FIGURE 8</label><caption><p>Funnel plots of intestinal metaplasia, map&#x02010;like redness, and xanthoma analyzed. (a) Intestinal metaplasia, (b) map&#x02010;like redness of all six articles, (c) map&#x02010;like redness of selected two articles, and (d) xanthoma.</p></caption><graphic xlink:href="DEO2-5-e70086-g003" position="anchor" id="jats-graphic-15"/></fig></sec><sec id="deo270086-sec-0190"><title>GC development with and without GC before eradication</title><p>In addition, evaluation of the number of post&#x02010;eradication GC in five with&#x02010;GC and seven without&#x02010;GC, which were all cohort and RCT articles, was demonstrated. GC group showed 205 of 2916 (7.03%) and without&#x02010;GC group showed 191 of 9673 (3.15%). The with&#x02010;GC group showed a significantly higher incidence of post&#x02010;eradication GC than the without&#x02010;GC group (<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.001; Table&#x000a0;<xref rid="deo270086-tbl-0005" ref-type="table">5</xref>).</p><table-wrap position="float" id="deo270086-tbl-0005" content-type="TABLE"><label>TABLE 5</label><caption><p>Gastric cancer (GC) development with or without GC before eradication.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">GC</th><th align="left" rowspan="1" colspan="1">Total</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">GC development with GC before eradication</td><td align="left" rowspan="1" colspan="1">Five articles</td><td align="left" rowspan="1" colspan="1">205 (7.03%)</td><td align="left" rowspan="1" colspan="1">2916</td><td align="left" rowspan="2" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">GC development without GC before eradication</td><td align="left" rowspan="1" colspan="1">Seven articles</td><td align="left" rowspan="1" colspan="1">191 (1.98%)</td><td align="left" rowspan="1" colspan="1">9673</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">12 articles</td><td align="left" rowspan="1" colspan="1">396 (3.15%)</td><td align="left" rowspan="1" colspan="1">12,586</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="deo270086-tbl5-note-0001"><p>GC: gastric cancer, Statistical analysis was used chi&#x02010;square test.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec id="deo270086-sec-0200"><title>DISCUSSION</title><p>An association between <italic toggle="yes">H. pylori</italic> eradication and GC has been disclosed by RCTs,<xref rid="deo270086-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="deo270086-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="deo270086-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> cohort studies<xref rid="deo270086-bib-0009" ref-type="bibr">,<sup>9</sup>
</xref> and meta&#x02010;analyses.<xref rid="deo270086-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="deo270086-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> Risk factors of post&#x02010;eradication GC have also been evaluated. Sugano reported in his meta&#x02010;analysis that the incidence of GC is significantly lower after eradication (odds ratio [OR] 0.46; 95&#x0ff05;CI: 0.39&#x02013;0.55).<xref rid="deo270086-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> However, to our knowledge, meta&#x02010;analysis and systematic review of endoscopic findings associated with the risk of post&#x02010;eradication GC has not been performed. Among the 66 articles selected for this study, four endoscopic findings were considered risk factors of post&#x02010;eradication GC: atrophy, IM, map&#x02010;like redness, and xanthoma. Other factors such as age, sex, medical history, and histologically confirmed inflammation were also reported previously as risk factors of post&#x02010;eradication GC,<xref rid="deo270086-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="deo270086-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="deo270086-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="deo270086-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="deo270086-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="deo270086-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> but were removed in this study except for factors related to endoscopic findings.</p><p>Overall, 19 papers were subjected to meta&#x02010;analysis after the exclusion of duplicates. Yan et&#x000a0;al. identified all four factors as risk factors,<xref rid="deo270086-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> while Shibukawa et&#x000a0;al. showed atrophy, IM, and map&#x02010;like redness as risk factors.<xref rid="deo270086-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> Five articles analyzed both atrophy and IM as risk factors.<xref rid="deo270086-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="deo270086-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="deo270086-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="deo270086-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>, <xref rid="deo270086-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> This result also indicated the close involvement of atrophy, IM, and map&#x02010;like redness in <italic toggle="yes">H. pylori</italic>&#x02010;infected gastric mucosa.</p><p>Classified by country, 12 articles were from Japan, six from China, and one from South Korea. In the meta&#x02010;analysis by Lee et&#x000a0;al.,<xref rid="deo270086-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> most articles were from East Asia (12 from Japan, four from China, one from Taiwan, and five from South Korea), with only one from Colombia and one from Finland. East Asian countries such as Japan, South Korea, and China account for about 70% of global GC incidence and mortality.<xref rid="deo270086-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="deo270086-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Geographic differences in GC prevalence suggest increased carcinogenicity of East Asian variants of <italic toggle="yes">H. pylori</italic> virulence factors such as CagA.<xref rid="deo270086-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>, <xref rid="deo270086-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> Therefore, <italic toggle="yes">H. pylori</italic> treatment and endoscopic screening for GC must be considered in East Asian countries.</p><sec id="deo270086-sec-0210"><title>Atrophy</title><p>Meta&#x02010;analysis of the ten articles on endoscopic atrophy and five on histologic atrophy yielded conflicting results but disclosed a 4&#x02010;fold risk of post&#x02010;eradication GC among patients with severe atrophy compared to those with absent or mild atrophy. Take et&#x000a0;al. reported a significant risk of post&#x02010;eradication GC for patients with endoscopic severe atrophy, with HR 14.4, 95% CI: 1.9&#x02013;110.2 (<italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.01) for baseline severe versus mild atrophy in 1674 successfully eradicated peptic ulcer cases in a prospective cohort study.<xref rid="deo270086-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> Although severe atrophy extending to the corpus was associated with a high risk of <italic toggle="yes">H. pylori</italic>&#x02010;infected GC previously,<xref rid="deo270086-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> the present study showed that open&#x02010;type severe endoscopic atrophy extending to the corpus was a significant risk factor for both pre&#x02010; and post&#x02010;eradication GC. The high heterogeneity (81%) observed in our study may be attributed to a mixture of endoscopic and histologic atrophy and differences in classifying the degree of endoscopic atrophy.</p><p>In the present study, the rate of metachronous GC after GC resection was significantly higher than that of GC without GC history. Sugano reported in his meta&#x02010;analysis that the GC incidence in the group with GC at baseline (5.26%) was higher than without GC (1.13%). Fukase also indicated that the post&#x02010;eradication GC incidence after GC resection (3.5%) was higher than that without eradication (9.6%). The present study showed similar GC incidence with or without GC history. However, sub&#x02010;analysis of both GC with and without GC at baseline showed significantly higher relative risks for severe atrophy. This suggests that atrophy is a major risk factor for GC after eradication, despite differences between with and without GC at eradication.</p><p>The Kimura&#x02010;Takemoto classification scheme is a globally accepted system that indicates the border of endoscopic atrophy, that is, the border between the fundic gland region and areas of metaplasia and/or pyloric glands.<xref rid="deo270086-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> Although this classification does not directly indicate the extent of histologically confirmed gastric atrophy, a significant correlation between endoscopic and histologically confirmed atrophy and IM of both the antrum and the corpus has been reported.<xref rid="deo270086-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>, <xref rid="deo270086-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="deo270086-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> Therefore, histologic and endoscopic atrophy were considered to be equivalent.</p><p>After eradication, histologic atrophy improves gradually,<xref rid="deo270086-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref>, <xref rid="deo270086-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="deo270086-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>, <xref rid="deo270086-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> while endoscopic atrophy is persistent.<xref rid="deo270086-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref> Most studies of the risk of post&#x02010;eradication GC have evaluated pre&#x02010;eradication baseline endoscopic atrophy. However, its negligible improvement after eradication suggests that advanced endoscopic atrophy may represent a high risk of incident GC at any post&#x02010;eradication time point. With the increasing number of cases with either an unknown history of eradication or spontaneous eradication, risk assessment&#x02010;based endoscopic atrophy is important at any time point after eradication.</p></sec><sec id="deo270086-sec-0220"><title>Intestinal metaplasia</title><p>This study included five articles on histologic<xref rid="deo270086-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="deo270086-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="deo270086-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="deo270086-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref>, <xref rid="deo270086-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref> and three articles on endoscopic IM.<xref rid="deo270086-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="deo270086-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="deo270086-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> According to the Kyoto classification of gastritis,<xref rid="deo270086-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> advanced IM extends beyond the vestibule to the corpus. Cases with IM extending into the corpus showed a nearly 9&#x02010;fold higher risk than the group without IM or with mild antral IM.</p><p>Unlike histologic atrophy, histologic IM is recalcitrant after eradication,<xref rid="deo270086-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> as confirmed by three meta&#x02010;analyses.<xref rid="deo270086-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>, <xref rid="deo270086-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref>, <xref rid="deo270086-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> Therefore, the extent of IM before eradication and also at any post&#x02010;eradication time point correlates with post&#x02010;eradication GC. Shichijo et&#x000a0;al. evaluated the distribution of endoscopic IM in three groups: no IM, IM confined to the antrum, and extension to the corpus,<xref rid="deo270086-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> and found that advanced IM increased the risk of post&#x02010;eradication GC. Multivariate analysis in our previous study also identified histologic IM of the corpus as the highest risk factor for post&#x02010;eradication GC.<xref rid="deo270086-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
</p><p>Takeuchi et&#x000a0;al. reported that IM is a precancerous gastric lesion based on DNA methylation profiles.<xref rid="deo270086-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> These epigenetic abnormalities, as well as atrophy, may be considered as mechanisms by which IM increases GC risk.</p></sec><sec id="deo270086-sec-0230"><title>Map&#x02010;like redness</title><p>In the present meta&#x02010;analysis, six articles on map&#x02010;like redness found that map&#x02010;like redness approximately doubled the risk of post&#x02010;eradication GC. We found no RCTs or prospective cohort studies on map&#x02010;like redness.</p><p>Because of the high heterogeneity of the analysis of Map&#x02010;like redness, a sub&#x02010;analysis of two prospective cohort studies was performed for sensitivity analysis. The RR was 2.54 in this analysis, suggesting that map&#x02010;like redness may be a useful risk predictor. However, the number of papers analyzed was only two, and further study is needed.</p><p>Moribata et&#x000a0;al. reported that post&#x02010;eradication map&#x02010;like redness correlated significantly with metachronous GC development.<xref rid="deo270086-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Majima et&#x000a0;al. found that endoscopic screening with linked color imaging (Fujifilm Medical Co. Ltd.) exhibited a higher recognition rate of map&#x02010;like redness than with observation under white light.<xref rid="deo270086-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref>
</p></sec><sec id="deo270086-sec-0240"><title>Xanthoma</title><p>Gastric xanthomas are white to yellowish sessile lesions with a fine granular surface found in <italic toggle="yes">H. pylori</italic>&#x02010;infected gastric mucosa. Histologic characteristics include aggregations of lipid&#x02010;phagocytosing histiocytes in the lamina propria. The morphology of xanthomas persists after <italic toggle="yes">H. pylori</italic> eradication. In the present study, both articles on the association between xanthoma and the risk of post&#x02010;eradication GC were retrospective studies<xref rid="deo270086-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="deo270086-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>; however, gastric xanthoma carried an approximately 7&#x02010;fold risk of post&#x02010;eradication GC. The multivariate logistic regression analysis conducted by Shibukawa et&#x000a0;al. identified gastric xanthoma as an independent predictor of early post&#x02010;eradication GC (OR 5.64, 95% CI 2.47&#x02013;12.9).<xref rid="deo270086-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>
</p><p>Many of the endoscopic findings that accompany active <italic toggle="yes">H. pylori</italic> infection improve or resolve after eradication. However, GC may occur more than 10 years after eradication. In addition, the number of cases with no known history of eradication is increasing.<xref rid="deo270086-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref>, <xref rid="deo270086-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> Many studies included in our analysis evaluated endoscopic atrophy, IM, and xanthoma before eradication. However, all these endoscopic findings persisted after eradication. These results suggest that even cases that occur more than 10 years after eradication or cases with an unknown history of eradication may be useful in assessing the risk of post&#x02010;eradication GC.</p><p>Eradication cannot completely inhibit GC. Take et&#x000a0;al. found GC 18.3 years after eradication.<xref rid="deo270086-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref> Kobayashi et&#x000a0;al. reported that invasive cancers diagnosed over ten years after eradication were likely to be more malignant in histological type and pathological stage.<xref rid="deo270086-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> In our previous study, absent endoscopic follow&#x02010;up was the risk of post&#x02010;eradication undifferentiated GC. <xref rid="deo270086-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Therefore, long&#x02010;term endoscopic screening must be performed in all cases, even after eradication. However, the indicators are necessary to improve endoscopic screening efficiency.</p><p>Many studies indicated that severe atrophy, IM, and Map&#x02010;like redness are associated with the risk of GC after eradication. However, there have been no reports using meta&#x02010;analysis or systematic review of endoscopic factors associated with the risk of post&#x02010;eradication GC. The strength of our study is that endoscopic risk factors and findings for GC diagnosis after eradication were confirmed by meta&#x02010;analysis for the first time.</p><p>Screening focusing on these factors may improve the accuracy of diagnosis of GC after eradication. In addition, further studies, including a large number of cases, may lead to the discovery of new screening methods and endoscopic risk factors.</p></sec><sec id="deo270086-sec-0250"><title>Limitations</title><p>Several limitations of this study must be acknowledged. First, the definitions of the degrees of atrophy and IM differed between studies. Histological and endoscopic evaluations were also examined together. Although the histological and endoscopic findings were correlated, separate analyses were considered necessary. In addition, studies that indicated O&#x02010;2 and O&#x02010;3 as severe atrophy according to the Kimura&#x02010;Takemoto classification and studies that rated atrophy only by its presence or absence were included, and no unanimous criteria were used.</p><p>Second, because of the selection of studies focusing on endoscopic findings related to post&#x02010;eradication GC, many retrospective case&#x02010;control studies were also included. Prospective studies of endoscopic findings observed in the present study will be necessary.</p><p>Third, in the funnel plot, some partial blanks were observed in the analysis of atrophy. This result is considered a possible publication bias. Because GC often develops from severe atrophy, the possibility that few studies correspond to the blank area of the funnel plot may be considered. Further accumulation of articles is needed.</p><p>In conclusion, we conducted a meta&#x02010;analysis and systematic review to extract endoscopic risks of post&#x02010;eradication GC. Endoscopic atrophy, IM, and xanthoma observed at pre&#x02010; and post&#x02010;eradication time points, and post&#x02010;eradication map&#x02010;like redness were suggested as endoscopic risk factors for post&#x02010;eradication GC. These results suggest the need for post&#x02010;eradication endoscopic screening and continued GC risk assessment with attention to these findings.</p></sec></sec><sec sec-type="COI-statement" id="deo270086-sec-0270"><title>CONFLICT OF INTEREST STATEMENT</title><p>None.</p></sec><sec id="deo270086-sec-0280"><title>PATIENT CONSENT STATEMENT</title><p>All procedures were performed in accordance with the ethical standards of the institutional review board of the Oita University Faculty of Medicine and with the Helsinki Declaration of 1964 and later versions.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="deo270086-supinfo-0001" position="float" content-type="local-data"/><supplementary-material id="deo270086-supitem-0001" position="float" content-type="local-data"><caption><p>
<bold>FIGURE S1</bold> Forest plot analyzing the occurrence of post&#x02010;eradication gastric cancer according to the severity of gastric atrophy, using a fixed&#x02010;effect model.</p></caption><media xlink:href="DEO2-5-e70086-s002.jpg"/></supplementary-material><supplementary-material id="deo270086-supitem-0002" position="float" content-type="local-data"><caption><p>
<bold>FIGURE S2</bold> Forest plot analyzing the occurrence of post&#x02010;eradication gastric cancer according to the severity of gastric atrophy, Sub&#x02010;analysis with and without GC at baseline, using a fixed&#x02010;effect model. (a) Forest plot of Atrophy without GC. (b) Forest plot of Atrophy with GC. GC: Gastric cancer.</p></caption><media xlink:href="DEO2-5-e70086-s001.jpg"/></supplementary-material><supplementary-material id="deo270086-supitem-0003" position="float" content-type="local-data"><caption><p>
<bold>FIGURE S3</bold> Forest plot analyzing the occurrence of post&#x02010;eradication gastric cancer according to the severity of intestinal metaplasia, using a fixed&#x02010;effect model. IM: intestinal metaplasia.</p></caption><media xlink:href="DEO2-5-e70086-s005.jpg"/></supplementary-material><supplementary-material id="deo270086-supitem-0004" position="float" content-type="local-data"><caption><p>
<bold>FIGURE S4</bold> Forest plot analyzing the occurrence of post&#x02010;eradication gastric cancer according to the post&#x02010;eradication onset of map&#x02010;like redness, using a fixed&#x02010;effect model. (a) Forest plot analyzed using all articles. (b) Forest plot analyzed using selected two prospective cohort studies.</p></caption><media xlink:href="DEO2-5-e70086-s006.jpg"/></supplementary-material><supplementary-material id="deo270086-supitem-0005" position="float" content-type="local-data"><caption><p>
<bold>FIGURE S5</bold> Forest plot analyzing the incidence of post&#x02010;eradication gastric cancer according to the appearance of xanthoma, using a fixed&#x02010;effect model.</p></caption><media xlink:href="DEO2-5-e70086-s008.jpg"/></supplementary-material><supplementary-material id="deo270086-supitem-0006" position="float" content-type="local-data"><caption><p>
<bold>FIGURE S6</bold> Funnel plots of atrophy analyzed, using a fixed&#x02010;effect model. (a) Atrophy of all 16 articles, (b) atrophy of seven articles without GC, and (c) atrophy of nine articles with GC.</p></caption><media xlink:href="DEO2-5-e70086-s004.jpg"/></supplementary-material><supplementary-material id="deo270086-supitem-0007" position="float" content-type="local-data"><caption><p>
<bold>FIGURE S7</bold> Funnel plots of intestinal metaplasia, map&#x02010;like redness, and xanthoma analyzed, using a fixed&#x02010;effect model. (a) Intestinal metaplasia, (b) map&#x02010;like redness of all six articles, (c) map&#x02010;like redness of selected two articles, and (d) xanthoma.</p></caption><media xlink:href="DEO2-5-e70086-s007.jpg"/></supplementary-material><supplementary-material id="deo270086-supitem-0008" position="float" content-type="local-data"><caption><p>PRISMA2020 checklist.</p></caption><media xlink:href="DEO2-5-e70086-s003.pdf"/></supplementary-material></sec></body><back><ack id="deo270086-sec-0260"><title>ACKNOWLEDGMENTS</title><p>This work was supported by The Japanese Society for <italic toggle="yes">Helicobacter</italic> Research.</p></ack><ref-list id="deo270086-bibl-0001"><title>REFERENCES</title><ref id="deo270086-bib-0001"><label>1</label><mixed-citation publication-type="book" id="deo270086-cit-0001">
<string-name>
<surname>Ferlay</surname>
<given-names>JEM</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Laversanne</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <source>Global Cancer Observatory: Cancer Today</source>, <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>International Agency for Research on Cancer [Internet]</publisher-name>, <year>2024</year>, Available from: <ext-link xlink:href="https://gco.iarc.who.int/today" ext-link-type="uri">https://gco.iarc.who.int/today</ext-link>
</mixed-citation></ref><ref id="deo270086-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="deo270086-cit-0002">
<string-name>
<surname>Ferlay</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Colombet</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Soerjomataram</surname>
<given-names>I</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods</article-title>. <source>Int J Cancer</source>
<year>2019</year>; <volume>144</volume>: <fpage>1941</fpage>&#x02013;<lpage>1953</lpage>.<pub-id pub-id-type="pmid">30350310</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="deo270086-cit-0003">
<string-name>
<surname>Uemura</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Okamoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yamamoto</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>
<italic toggle="yes">Helicobacter pylori</italic> infection and the development of gastric cancer</article-title>. <source>N Engl J Med</source>
<year>2001</year>; <volume>345</volume>: <fpage>784</fpage>&#x02013;<lpage>789</lpage>.<pub-id pub-id-type="pmid">11556297</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="deo270086-cit-0004">
<string-name>
<surname>Herrero</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Forman</surname>
<given-names>D</given-names>
</string-name>. <article-title>The fight against gastric cancer &#x02013; The IARC Working Group report</article-title>. <source>Best Pract Res Clin Gastroenterol</source>
<year>2014</year>; <volume>28</volume>: <fpage>1107</fpage>&#x02013;<lpage>1114</lpage>.<pub-id pub-id-type="pmid">25439075</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="deo270086-cit-0005">
<string-name>
<surname>Take</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mizuno</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ishiki</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>The effect of eradicating <italic toggle="yes">Helicobacter pylori</italic> on the development of gastric cancer in patients with peptic ulcer disease</article-title>. <source>Am J Gastroenterol</source>
<year>2005</year>; <volume>100</volume>: <fpage>1037</fpage>&#x02013;<lpage>1042</lpage>.<pub-id pub-id-type="pmid">15842576</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="deo270086-cit-0006">
<string-name>
<surname>Fukase</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kikuchi</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Effect of eradication of <italic toggle="yes">Helicobacter pylori</italic> on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open&#x02010;label, randomised controlled trial</article-title>. <source>Lancet</source>
<year>2008</year>; <volume>372</volume>: <fpage>392</fpage>&#x02013;<lpage>397</lpage>.<pub-id pub-id-type="pmid">18675689</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="deo270086-cit-0007">
<string-name>
<surname>Ford</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Forman</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hunt</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Moayyedi</surname>
<given-names>P</given-names>
</string-name>. <article-title>
<italic toggle="yes">Helicobacter pylori</italic> eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: Systematic review and meta&#x02010;analysis of randomised controlled trials</article-title>. <source>BMJ</source>
<year>2014</year>; <volume>348</volume>: <elocation-id>g3174</elocation-id>.<pub-id pub-id-type="pmid">24846275</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="deo270086-cit-0008">
<string-name>
<surname>Yoon</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>YK</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>MG</given-names>
</string-name>. <article-title>Effect of <italic toggle="yes">Helicobacter pylori</italic> eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: A meta&#x02010;analysis</article-title>. <source>Helicobacter</source>
<year>2014</year>; <volume>19</volume>: <fpage>243</fpage>&#x02013;<lpage>248</lpage>.<pub-id pub-id-type="pmid">25056262</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="deo270086-cit-0009">
<string-name>
<surname>Take</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mizuno</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ishiki</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Seventeen&#x02010;year effects of eradicating <italic toggle="yes">Helicobacter pylori</italic> on the prevention of gastric cancer in patients with peptic ulcer; A prospective cohort study</article-title>. <source>J Gastroenterol</source>
<year>2015</year>; <volume>50</volume>: <fpage>638</fpage>&#x02013;<lpage>644</lpage>.<pub-id pub-id-type="pmid">25351555</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="deo270086-cit-0010">
<string-name>
<surname>Wei</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Min</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>C</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Endoscopic characteristics and high&#x02010;risk background mucosa factors of early gastric cancer after <italic toggle="yes">Helicobacter pylori</italic> eradication: A single&#x02010;center retrospective study</article-title>. <source>Front Oncol</source>
<year>2023</year>; <volume>13</volume>: <elocation-id>1272187</elocation-id>.<pub-id pub-id-type="pmid">37849804</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="deo270086-cit-0011">
<string-name>
<surname>Yamamoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Clinicopathological analysis of early&#x02010;stage gastric cancers detected after successful eradication of <italic toggle="yes">Helicobacter pylori</italic>
</article-title>. <source>Helicobacter</source>
<year>2011</year>; <volume>16</volume>: <fpage>210</fpage>&#x02013;<lpage>216</lpage>.<pub-id pub-id-type="pmid">21585606</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="deo270086-cit-0012">
<string-name>
<surname>Kodama</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Okimoto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Mizukami</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Endoscopic and Immunohistochemical Characteristics of Gastric Cancer with versus without <italic toggle="yes">Helicobacter pylori</italic> Eradication</article-title>. <source>Digestion</source>
<year>2018</year>; <volume>97</volume>: <fpage>288</fpage>&#x02013;<lpage>297</lpage>.<pub-id pub-id-type="pmid">29514141</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="deo270086-cit-0013">
<string-name>
<surname>Kobayashi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sato</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Terai</surname>
<given-names>S</given-names>
</string-name>. <article-title>Endoscopic surveillance of gastric cancers after <italic toggle="yes">Helicobacter pylori</italic> eradication</article-title>. <source>World J Gastroenterol</source>
<year>2015</year>; <volume>21</volume>: <fpage>10553</fpage>&#x02013;<lpage>10562</lpage>.<pub-id pub-id-type="pmid">26457015</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="deo270086-cit-0014">
<string-name>
<surname>Kitamura</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ito</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Matsuo</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Characteristic epithelium with low&#x02010;grade atypia appears on the surface of gastric cancer after successful <italic toggle="yes">Helicobacter pylori</italic> eradication therapy</article-title>. <source>Helicobacter</source>
<year>2014</year>; <volume>19</volume>: <fpage>289</fpage>&#x02013;<lpage>295</lpage>.<pub-id pub-id-type="pmid">24766284</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="deo270086-cit-0015">
<string-name>
<surname>Masuda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Urabe</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ito</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Genomic landscape of epithelium with low&#x02010;grade atypia on gastric cancer after <italic toggle="yes">Helicobacter pylori</italic> eradication therapy</article-title>. <source>J Gastroenterol</source>
<year>2019</year>; <volume>54</volume>: <fpage>907</fpage>&#x02013;<lpage>915</lpage>.<pub-id pub-id-type="pmid">31197475</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="deo270086-cit-0016">
<string-name>
<surname>Ito</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Takata</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Morphological changes in human gastric tumours after eradication therapy of <italic toggle="yes">Helicobacter pylori</italic> in a short&#x02010;term follow&#x02010;up</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2005</year>; <volume>21</volume>: <fpage>559</fpage>&#x02013;<lpage>566</lpage>.<pub-id pub-id-type="pmid">15740539</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="deo270086-cit-0017">
<string-name>
<surname>Kim</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>YS</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>SI</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease</article-title>. <source>Helicobacter</source>
<year>2008</year>; <volume>13</volume>: <fpage>245</fpage>&#x02013;<lpage>255</lpage>.<pub-id pub-id-type="pmid">18665932</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="deo270086-cit-0018">
<string-name>
<surname>Kodama</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Murakami</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Okimoto</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Histological characteristics of gastric mucosa prior to <italic toggle="yes">Helicobacter pylori</italic> eradication may predict gastric cancer</article-title>. <source>Scand J Gastroenterol</source>
<year>2013</year>; <volume>48</volume>: <fpage>1249</fpage>&#x02013;<lpage>1256</lpage>.<pub-id pub-id-type="pmid">24079881</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="deo270086-cit-0019">
<string-name>
<surname>Kwon</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>SY</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>JH</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>ABC Classification Is Less Useful for Older Koreans Born before 1960</article-title>. <source>Gut Liver</source>
<year>2019</year>; <volume>13</volume>: <fpage>522</fpage>&#x02013;<lpage>530</lpage>.<pub-id pub-id-type="pmid">30970432</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="deo270086-cit-0020">
<string-name>
<surname>Kodama</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mizukami</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hirashita</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Differences in clinical features and morphology between differentiated and undifferentiated gastric cancer after <italic toggle="yes">Helicobacter pylori</italic> eradication</article-title>. <source>PLoS One</source>
<year>2023</year>; <volume>18</volume>: <elocation-id>e0282341</elocation-id>.<pub-id pub-id-type="pmid">37000845</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="deo270086-cit-0021">
<string-name>
<surname>Ford</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Forman</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hunt</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Moayyedi</surname>
<given-names>P</given-names>
</string-name>. <article-title>
<italic toggle="yes">Helicobacter pylori</italic> eradication for the prevention of gastric neoplasia</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2015</year>; <volume>2015</volume>: <elocation-id>CD005583</elocation-id>.<pub-id pub-id-type="pmid">26198377</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="deo270086-cit-0022">
<string-name>
<surname>Lee</surname>
<given-names>YC</given-names>
</string-name>, <string-name>
<surname>Chiang</surname>
<given-names>TH</given-names>
</string-name>, <string-name>
<surname>Chou</surname>
<given-names>CK</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Association Between <italic toggle="yes">Helicobacter pylori</italic> eradication and gastric cancer incidence: A systematic review and meta&#x02010;analysis</article-title>. <source>Gastroenterology</source>
<year>2016</year>; <volume>150</volume>: <fpage>1113</fpage>&#x02013;<lpage>1124.e5</lpage>.<pub-id pub-id-type="pmid">26836587</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="deo270086-cit-0023">
<string-name>
<surname>Sugano</surname>
<given-names>K</given-names>
</string-name>. <article-title>Effect of <italic toggle="yes">Helicobacter pylori</italic> eradication on the incidence of gastric cancer: A systematic review and meta&#x02010;analysis</article-title>. <source>Gastric Cancer</source>
<year>2019</year>; <volume>22</volume>: <fpage>435</fpage>&#x02013;<lpage>445</lpage>.<pub-id pub-id-type="pmid">30206731</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="deo270086-cit-0024">
<string-name>
<surname>Sugimoto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Murata</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yamaoka</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Chemoprevention of gastric cancer development after <italic toggle="yes">Helicobacter pylori</italic> eradication therapy in an East Asian population: Meta&#x02010;analysis</article-title>. <source>World J Gastroenterol</source>
<year>2020</year>; <volume>26</volume>: <fpage>1820</fpage>&#x02013;<lpage>1840</lpage>.<pub-id pub-id-type="pmid">32351296</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="deo270086-cit-0025">
<string-name>
<surname>Dixon</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Genta</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Yardley</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Correa</surname>
<given-names>P</given-names>
</string-name>. <article-title>Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994</article-title>. <source>Am J Surg Pathol</source>
<year>1996</year>; <volume>20</volume>: <fpage>1161</fpage>&#x02013;<lpage>1181</lpage>.<pub-id pub-id-type="pmid">8827022</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="deo270086-cit-0026">
<string-name>
<surname>Kimura</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Takemoto</surname>
<given-names>T</given-names>
</string-name>. <article-title>An endoscopic recognition of the atrophic border and its significance in chronic gastritis</article-title>. <source>Endoscopy</source>
<year>1969</year>; <volume>1</volume>: <fpage>87</fpage>&#x02013;<lpage>97</lpage>.</mixed-citation></ref><ref id="deo270086-bib-0027"><label>27</label><mixed-citation publication-type="book" id="deo270086-cit-0027">
<string-name>
<surname>Haruma</surname>
<given-names>K</given-names>
</string-name>. <string-name>
<surname>Kato</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Inoue</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Murakami</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kamada</surname>
<given-names>T</given-names>
</string-name>. <source>Kyoto Classification of Gastritis</source>, <publisher-loc>Tokyo</publisher-loc>: <publisher-name>Nihon Medical Center</publisher-name>, <year>2017</year>.</mixed-citation></ref><ref id="deo270086-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="deo270086-cit-0028">
<string-name>
<surname>Uedo</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ishihara</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Iishi</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>A new method of diagnosing gastric intestinal metaplasia: Narrow&#x02010;band imaging with magnifying endoscopy</article-title>. <source>Endoscopy</source>
<year>2006</year>; <volume>38</volume>: <fpage>819</fpage>&#x02013;<lpage>824</lpage>.<pub-id pub-id-type="pmid">17001572</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="deo270086-cit-0029">
<string-name>
<surname>Yao</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Iwashita</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nambu</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Nature of white opaque substance in gastric epithelial neoplasia as visualized by magnifying endoscopy with narrow&#x02010;band imaging</article-title>. <source>Dig Endosc</source>
<year>2012</year>; <volume>24</volume>: <fpage>419</fpage>&#x02013;<lpage>425</lpage>.<pub-id pub-id-type="pmid">23078433</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="deo270086-cit-0030">
<string-name>
<surname>Moribata</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Iguchi</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Nakachi</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Endoscopic features associated with development of metachronous gastric cancer in patients who underwent endoscopic resection followed by <italic toggle="yes">Helicobacter pylori</italic> eradication</article-title>. <source>Dig Endosc</source>
<year>2016</year>; <volume>28</volume>: <fpage>434</fpage>&#x02013;<lpage>442</lpage>.<pub-id pub-id-type="pmid">26623565</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="deo270086-cit-0031">
<string-name>
<surname>Matsumoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sugimoto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fukuzawa</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Risk of map&#x02010;like redness development after eradication therapy for <italic toggle="yes">Helicobacter pylori</italic> infection</article-title>. <source>Helicobacter</source>
<year>2024</year>; <volume>29</volume>: <elocation-id>e13046</elocation-id>.<pub-id pub-id-type="pmid">38984721</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="deo270086-cit-0032">
<string-name>
<surname>Yan</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>F</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Effect of <italic toggle="yes">Helicobacter pylori</italic> eradication on gastric cancer prevention: Updated report from a randomized controlled trial with 26.5 years of follow&#x02010;up</article-title>. <source>Gastroenterology</source>
<year>2022</year>; <volume>163</volume>: <fpage>154</fpage>&#x02013;<lpage>162.e3</lpage>.<pub-id pub-id-type="pmid">35364066</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="deo270086-cit-0033">
<string-name>
<surname>Choi</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>J</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Effects of <italic toggle="yes">Helicobacter pylori</italic> eradication for metachronous gastric cancer prevention: A randomized controlled trial</article-title>. <source>Gastrointest Endosc</source>
<year>2018</year>; <volume>88</volume>: 475&#x02013;485 e2.</mixed-citation></ref><ref id="deo270086-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="deo270086-cit-0034">
<string-name>
<surname>Ford</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Moayyedi</surname>
<given-names>P</given-names>
</string-name>. <article-title>
<italic toggle="yes">Helicobacter pylori</italic> eradication therapy to prevent gastric cancer: Systematic review and meta&#x02010;analysis</article-title>. <source>Gut</source>
<year>2020</year>; <volume>69</volume>: <fpage>2113</fpage>&#x02013;<lpage>2121</lpage>.<pub-id pub-id-type="pmid">32205420</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="deo270086-cit-0035">
<string-name>
<surname>Uemura</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mukai</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Okamoto</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Effect of <italic toggle="yes">Helicobacter pylori</italic> eradication on subsequent development of cancer after endoscopic resection of early gastric cancer</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>
<year>1997</year>; <volume>6</volume>: <fpage>639</fpage>&#x02013;<lpage>642</lpage>.<pub-id pub-id-type="pmid">9264278</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="deo270086-cit-0036">
<string-name>
<surname>Wong</surname>
<given-names>BC</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>WM</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>
<italic toggle="yes">Helicobacter pylori</italic> eradication to prevent gastric cancer in a high&#x02010;risk region of China: A randomized controlled trial</article-title>. <source>JAMA</source>
<year>2004</year>; <volume>291</volume>: <fpage>187</fpage>&#x02013;<lpage>194</lpage>.<pub-id pub-id-type="pmid">14722144</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="deo270086-cit-0037">
<string-name>
<surname>Take</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mizuno</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ishiki</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after <italic toggle="yes">Helicobacter pylori</italic> eradication therapy in patients with peptic ulcer diseases</article-title>. <source>J Gastroenterol</source>
<year>2007</year>; <volume>42</volume> (Suppl <issue>17</issue>): <fpage>21</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">17238021</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="deo270086-cit-0038">
<string-name>
<surname>Rokkas</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sechopoulos</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pistiolas</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Margantinis</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Koukoulis</surname>
<given-names>G</given-names>
</string-name>. <article-title>
<italic toggle="yes">Helicobacter pylori</italic> infection and gastric histology in first&#x02010;degree relatives of gastric cancer patients: A meta&#x02010;analysis</article-title>. <source>Eur J Gastroenterol Hepatol</source>
<year>2010</year>; <volume>22</volume>: <fpage>1128</fpage>&#x02013;<lpage>1133</lpage>.<pub-id pub-id-type="pmid">20410824</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="deo270086-cit-0039">
<string-name>
<surname>Kosunen</surname>
<given-names>TU</given-names>
</string-name>, <string-name>
<surname>Pukkala</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sarna</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Gastric cancers in Finnish patients after cure of <italic toggle="yes">Helicobacter pylori</italic> infection: A cohort study</article-title>. <source>Int J Cancer</source>
<year>2011</year>; <volume>128</volume>: <fpage>433</fpage>&#x02013;<lpage>439</lpage>.<pub-id pub-id-type="pmid">20309944</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="deo270086-cit-0040">
<string-name>
<surname>Yan</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Duan</surname>
<given-names>B</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Exploration of endoscopic findings and risk factors of early gastric cancer after eradication of <italic toggle="yes">Helicobacter pylori</italic>
</article-title>. <source>Scand J Gastroenterol</source>
<year>2021</year>; <volume>56</volume>: <fpage>356</fpage>&#x02013;<lpage>362</lpage>.<pub-id pub-id-type="pmid">33410344</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="deo270086-cit-0041">
<string-name>
<surname>Shibukawa</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ouchi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wakamatsu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wakahara</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kaneko</surname>
<given-names>A</given-names>
</string-name>. <article-title>Gastric xanthoma is a predictive marker for early gastric cancer detected after <italic toggle="yes">Helicobacter pylori</italic> eradication</article-title>. <source>Intern Med</source>
<year>2019</year>; <volume>58</volume>: <fpage>779</fpage>&#x02013;<lpage>784</lpage>.<pub-id pub-id-type="pmid">30449773</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="deo270086-cit-0042">
<string-name>
<surname>Hara</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Okamura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Iwaya</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nagaya</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ota</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Umemura</surname>
<given-names>T</given-names>
</string-name>. <article-title>Histopathologically defined intestinal metaplasia in lesser curvature of corpus prior to <italic toggle="yes">Helicobacter pylori</italic> eradication is a risk factor for gastric cancer development</article-title>. <source>Helicobacter</source>
<year>2022</year>; <volume>27</volume>: <elocation-id>e12934</elocation-id>.<pub-id pub-id-type="pmid">36263778</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="deo270086-cit-0043">
<string-name>
<surname>Shichijo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hirata</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Characteristics and predictors of gastric cancer after <italic toggle="yes">Helicobacter pylori</italic> eradication</article-title>. <source>World J Gastroenterol</source>
<year>2018</year>; <volume>24</volume>: <fpage>2163</fpage>&#x02013;<lpage>2172</lpage>.<pub-id pub-id-type="pmid">29853734</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="deo270086-cit-0044">
<string-name>
<surname>Azuma</surname>
<given-names>T</given-names>
</string-name>. <article-title>
<italic toggle="yes">Helicobacter pylori</italic> CagA protein variation associated with gastric cancer in Asia</article-title>. <source>J Gastroenterol</source>
<year>2004</year>; <volume>39</volume>: <fpage>97</fpage>&#x02013;<lpage>103</lpage>.<pub-id pub-id-type="pmid">15069615</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="deo270086-cit-0045">
<string-name>
<surname>Yamaoka</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Mechanisms of disease: <italic toggle="yes">Helicobacter pylori</italic> virulence factors</article-title>. <source>Nat Rev Gastroenterol Hepatol</source>
<year>2010</year>; <volume>7</volume>: <fpage>629</fpage>&#x02013;<lpage>641</lpage>.<pub-id pub-id-type="pmid">20938460</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="deo270086-cit-0046">
<string-name>
<surname>Take</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mizuno</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ishiki</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>The long&#x02010;term risk of gastric cancer after the successful eradication of <italic toggle="yes">Helicobacter pylori</italic>
</article-title>. <source>J Gastroenterol</source>
<year>2011</year>; <volume>46</volume>: <fpage>318</fpage>&#x02013;<lpage>324</lpage>.<pub-id pub-id-type="pmid">21103997</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="deo270086-cit-0047">
<string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Vosmaer</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Tytgat</surname>
<given-names>GN</given-names>
</string-name>, <string-name>
<surname>Xiao</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Ten Kate</surname>
<given-names>FJ</given-names>
</string-name>. <article-title>Gastrin (G) cells and somatostatin (D) cells in patients with dyspeptic symptoms: <italic toggle="yes">Helicobacter pylori</italic> associated and non&#x02010;associated gastritis</article-title>. <source>J Clin Pathol</source>
<year>2005</year>; <volume>58</volume>: <fpage>927</fpage>&#x02013;<lpage>931</lpage>.<pub-id pub-id-type="pmid">16126872</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="deo270086-cit-0048">
<string-name>
<surname>Quach</surname>
<given-names>DT</given-names>
</string-name>, <string-name>
<surname>Le</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Hiyama</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nguyen</surname>
<given-names>OT</given-names>
</string-name>, <string-name>
<surname>Nguyen</surname>
<given-names>TS</given-names>
</string-name>, <string-name>
<surname>Uemura</surname>
<given-names>N</given-names>
</string-name>. <article-title>Relationship between endoscopic and histologic gastric atrophy and intestinal metaplasia</article-title>. <source>Helicobacter</source>
<year>2013</year>; <volume>18</volume>: <fpage>151</fpage>&#x02013;<lpage>157</lpage>.<pub-id pub-id-type="pmid">23167960</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="deo270086-cit-0049">
<string-name>
<surname>Kodama</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Okimoto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ogawa</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mizukami</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Murakami</surname>
<given-names>K</given-names>
</string-name>. <article-title>Endoscopic atrophic classification before and after <italic toggle="yes">H. pylori</italic> eradication is closely associated with histological atrophy and intestinal metaplasia</article-title>. <source>Endosc Int Open</source>
<year>2015</year>; <volume>3</volume>: <fpage>E311</fpage>&#x02013;<lpage>E317</lpage>.<pub-id pub-id-type="pmid">26357676</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="deo270086-cit-0050">
<string-name>
<surname>Kodama</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Murakami</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Okimoto</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Ten&#x02010;year prospective follow&#x02010;up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after <italic toggle="yes">Helicobacter pylori</italic> eradication</article-title>. <source>J Gastroenterol</source>
<year>2012</year>; <volume>47</volume>: <fpage>394</fpage>&#x02013;<lpage>403</lpage>.<pub-id pub-id-type="pmid">22138891</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="deo270086-cit-0051">
<string-name>
<surname>Rokkas</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Rokka</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Portincasa</surname>
<given-names>P</given-names>
</string-name>. <article-title>A systematic review and meta&#x02010;analysis of the role of <italic toggle="yes">Helicobacter pylori</italic> eradication in preventing gastric cancer</article-title>. <source>Ann Gastroenterol</source>
<year>2017</year>; <volume>30</volume>: <fpage>414</fpage>&#x02013;<lpage>423</lpage>.<pub-id pub-id-type="pmid">28655977</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="deo270086-cit-0052">
<string-name>
<surname>Kong</surname>
<given-names>YJ</given-names>
</string-name>, <string-name>
<surname>Yi</surname>
<given-names>HG</given-names>
</string-name>, <string-name>
<surname>Dai</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>MX</given-names>
</string-name>. <article-title>Histological changes of gastric mucosa after <italic toggle="yes">Helicobacter pylori</italic> eradication: A systematic review and meta&#x02010;analysis</article-title>. <source>World J Gastroenterol</source>
<year>2014</year>; <volume>20</volume>: <fpage>5903</fpage>&#x02013;<lpage>5911</lpage>.<pub-id pub-id-type="pmid">24914352</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="deo270086-cit-0053">
<string-name>
<surname>Hwang</surname>
<given-names>YJ</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>HS</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Reversibility of atrophic gastritis and intestinal metaplasia after <italic toggle="yes">Helicobacter pylori</italic> eradication &#x02013; A prospective study for up to 10 years</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2018</year>; <volume>47</volume>: <fpage>380</fpage>&#x02013;<lpage>390</lpage>.<pub-id pub-id-type="pmid">29193217</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="deo270086-cit-0054">
<string-name>
<surname>Fukuda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kodama</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mizukami</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Analysis of long&#x02010;term serological and histological changes after eradication of <italic toggle="yes">Helicobacter pylori</italic>
</article-title>. <source>J Clin Biochem Nutr</source>
<year>2022</year>; <volume>71</volume>: <fpage>151</fpage>&#x02013;<lpage>157</lpage>.<pub-id pub-id-type="pmid">36213784</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="deo270086-cit-0055">
<string-name>
<surname>Shichijo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hirata</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Niikura</surname>
<given-names>R</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after <italic toggle="yes">Helicobacter pylori</italic> eradication</article-title>. <source>Gastrointest Endosc</source>
<year>2016</year>; <volume>84</volume>: <fpage>618</fpage>&#x02013;<lpage>624</lpage>.<pub-id pub-id-type="pmid">26995689</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="deo270086-cit-0056">
<string-name>
<surname>Choi</surname>
<given-names>IJ</given-names>
</string-name>, <string-name>
<surname>Kook</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>YI</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>
<italic toggle="yes">Helicobacter pylori</italic> therapy for the prevention of metachronous gastric cancer</article-title>. <source>N Engl J Med</source>
<year>2018</year>; <volume>378</volume>: <fpage>1085</fpage>&#x02013;<lpage>1095</lpage>.<pub-id pub-id-type="pmid">29562147</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="deo270086-cit-0057">
<string-name>
<surname>Rokkas</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Pistiolas</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Sechopoulos</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Robotis</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Margantinis</surname>
<given-names>G</given-names>
</string-name>. <article-title>The long&#x02010;term impact of <italic toggle="yes">Helicobacter pylori</italic> eradication on gastric histology: A systematic review and meta&#x02010;analysis</article-title>. <source>Helicobacter</source>
<year>2007</year>; <volume>12</volume> (Suppl <issue>2</issue>): <fpage>32</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">17991174</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="deo270086-cit-0058">
<string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>R</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Gastric atrophy and intestinal metaplasia before and after <italic toggle="yes">Helicobacter pylori</italic> eradication: A meta&#x02010;analysis</article-title>. <source>Digestion</source>
<year>2011</year>; <volume>83</volume>: <fpage>253</fpage>&#x02013;<lpage>260</lpage>.<pub-id pub-id-type="pmid">21282951</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="deo270086-cit-0059">
<string-name>
<surname>Takeuchi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Yamashita</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>YY</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Precancerous nature of intestinal metaplasia with increased chance of conversion and accelerated DNA methylation</article-title>. <source>Gut</source>
<year>2024</year>; <volume>73</volume>: <fpage>255</fpage>&#x02013;<lpage>267</lpage>.<pub-id pub-id-type="pmid">37751933</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="deo270086-cit-0060">
<string-name>
<surname>Majima</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dohi</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Takayama</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Linked color imaging identifies important risk factors associated with gastric cancer after successful eradication of <italic toggle="yes">Helicobacter pylori</italic>
</article-title>. <source>Gastrointest Endosc</source>
<year>2019</year>; <volume>90</volume>: <fpage>763</fpage>&#x02013;<lpage>769</lpage>.<pub-id pub-id-type="pmid">31299258</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="deo270086-cit-0061">
<string-name>
<surname>Take</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mizuno</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ishiki</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Risk of gastric cancer in the second decade of follow&#x02010;up after <italic toggle="yes">Helicobacter pylori</italic> eradication</article-title>. <source>J Gastroenterol</source>
<year>2020</year>; <volume>55</volume>: <fpage>281</fpage>&#x02013;<lpage>288</lpage>.<pub-id pub-id-type="pmid">31667586</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="deo270086-cit-0062">
<string-name>
<surname>Kobayashi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fujisaki</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Namikawa</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Multicenter study of invasive gastric cancer detected after 10 years of <italic toggle="yes">Helicobacter pylori</italic> eradication in Japan: Clinical, endoscopic, and histopathologic characteristics</article-title>. <source>DEN Open</source>
<year>2024</year>; <volume>4</volume>: <elocation-id>e345</elocation-id>.<pub-id pub-id-type="pmid">38434145</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="deo270086-cit-0063">
<string-name>
<surname>Kamada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hata</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sugiu</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Clinical features of gastric cancer discovered after successful eradication of <italic toggle="yes">Helicobacter pylori</italic>: Results from a 9&#x02010;year prospective follow&#x02010;up study in Japan</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2005</year>; <volume>21</volume>: <fpage>1121</fpage>&#x02013;<lpage>1126</lpage>.<pub-id pub-id-type="pmid">15854174</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="deo270086-cit-0064">
<string-name>
<surname>Kwon</surname>
<given-names>YH</given-names>
</string-name>, <string-name>
<surname>Heo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Jeon</surname>
<given-names>SW</given-names>
</string-name>. <article-title>Failure of <italic toggle="yes">Helicobacter pylori</italic> eradication and age are independent risk factors for recurrent neoplasia after endoscopic resection of early gastric cancer in 283 patients</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2014</year>; <volume>39</volume>: <fpage>609</fpage>&#x02013;<lpage>618</lpage>.<pub-id pub-id-type="pmid">24461252</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="deo270086-cit-0065">
<string-name>
<surname>Toyoshima</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Yamaji</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yoshida</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Endoscopic gastric atrophy is strongly associated with gastric cancer development after <italic toggle="yes">Helicobacter pylori</italic> eradication</article-title>. <source>Surg Endosc</source>
<year>2017</year>; <volume>31</volume>: <fpage>2140</fpage>&#x02013;<lpage>2148</lpage>.<pub-id pub-id-type="pmid">27604367</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="deo270086-cit-0066">
<string-name>
<surname>Kato</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hayashi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nishida</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>
<italic toggle="yes">Helicobacter pylori</italic> eradication prevents secondary gastric cancer in patients with mild&#x02010;to&#x02010;moderate atrophic gastritis</article-title>. <source>J Gastroenterol Hepatol</source>
<year>2021</year>; <volume>36</volume>: <fpage>2083</fpage>&#x02013;<lpage>2090</lpage>.<pub-id pub-id-type="pmid">33403702</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="deo270086-cit-0067">
<string-name>
<surname>Hanaoka</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Uedo</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Shiotani</surname>
<given-names>A</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Autofluorescence imaging for predicting development of metachronous gastric cancer after <italic toggle="yes">Helicobacter pylori</italic> eradication</article-title>. <source>J Gastroenterol Hepatol</source>
<year>2010</year>; <volume>25</volume>: <fpage>1844</fpage>&#x02013;<lpage>1849</lpage>.<pub-id pub-id-type="pmid">21091995</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="deo270086-cit-0068">
<string-name>
<surname>Maehata</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fujisawa</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Long&#x02010;term effect of <italic toggle="yes">Helicobacter pylori</italic> eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer</article-title>. <source>Gastrointest Endosc</source>
<year>2012</year>; <volume>75</volume>: <fpage>39</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">22018552</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="deo270086-cit-0069">
<string-name>
<surname>Take</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mizuno</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ishiki</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Correction to: Risk of gastric cancer in the second decade of follow&#x02010;up after <italic toggle="yes">Helicobacter pylori</italic> eradication</article-title>. <source>J Gastroenterol</source>
<year>2020</year>; <volume>55</volume>: <fpage>289</fpage>&#x02013;<lpage>290</lpage>.<pub-id pub-id-type="pmid">31820091</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="deo270086-cit-0070">
<string-name>
<surname>Ohno</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Miyoshi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>A</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Endoscopic severe mucosal atrophy indicates the presence of gastric cancer after <italic toggle="yes">Helicobacter pylori</italic> eradication &#x02010;analysis based on the Kyoto classification</article-title>. <source>BMC Gastroenterol</source>
<year>2020</year>; <volume>20</volume>: <fpage>232</fpage>.<pub-id pub-id-type="pmid">32689949</pub-id>
</mixed-citation></ref><ref id="deo270086-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="deo270086-cit-0071">
<string-name>
<surname>Liu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Mao</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Characteristic analysis of early gastric cancer after <italic toggle="yes">Helicobacter pylori</italic> eradication: A multicenter retrospective propensity score&#x02010;matched study</article-title>. <source>Ann Med</source>
<year>2023</year>; <volume>55</volume>: <elocation-id>2231852</elocation-id>.<pub-id pub-id-type="pmid">37450336</pub-id>
</mixed-citation></ref></ref-list></back></article>